Lilly’s donanemab will face an Alzheimer’s adcomm in June, setting the stage for a Leqembi showdown

The FDA announced a June advisory committee date, potentially introducing a new Alzheimer’s treatment to compete with Eisai and Biogen’s Leqembi.